• About us
• Contact

Advertisement

Organisation › Details

Helsinn Investment Fund S.A., SICAR

About 3B Future Health Fund S.A. SICAR, formerly known as Helsinn Investment Fund S.A., SICAR 3B Future Health Fund is focused on investments in areas of high unmet patient need. Backed by the Helsinn Group, and guided by Helsinn’s core values of quality, integrity and respect, 3B Future Health Fund aims to help companies with innovative technologies to transform new ideas into commercial solutions with the potential to impact health-related quality of life of patients. Drawing on Helsinn’s over 40 years of investment into research and development and commercial expertise, the investment fund selects companies with technologies in a range of areas including cancer therapeutics and diagnostics, cancer supportive care, metabolic and gastrointestinal disorders, and dermatology conditions. *

 

	Start	2016-10-16 existent
	End	2020-07-14 renamed data ca.
	Group	Helsinn (Group)
	Today	3B Future Health Fund S.A. SICAR
	Successor	3B Future Health Fund S.A. SICAR
	Industry	financial services
	Person	Braglia, Riccardo (Helsinn Healthcare 200602 Managing Director)
	Street	412F route d’Esch
	City	2086 Luxembourg
		Address record changed: 2020-12-02
Basic data	Employees	n. a.
	Currency	USD
	Annual sales	50,000,000 (capital, committed 2016-10-10)
		* Document for »About Section«: iOnctura S.A.. (7/14/20). "Press Release: iOnctura Extends Series A to EUR 20.1m". Geneva.
		Record changed: 2024-02-12

Advertisement

More documents for Helsinn (Group)

• [1] iOnctura S.A.. (7/14/20). "Press Release: iOnctura Extends Series A to EUR 20.1m". Geneva....
• [2] NovellusDx Ltd.. (4/30/18). "Press Release: NovellusDx Announced It Has Completed an Equity Financing of $6 Million". Jerusalem....
• [3] Helsinn Healthcare S.A.. (1/30/18). "Press Release: Helsinn and the Scientific Centre of Monaco Sign Collaboration Agreement". Lugano....
• [4] Helsinn Healthcare S.A.. (6/16/17). "Press Release: Helsinn Investment Fund Leads the Financial Round in GreenBone". Lugano....
• [5] Helsinn Healthcare S.A.. (6/12/17). "Press Release: Zealand to Regain Control of Elsiglutide. Helsinn Returns Elsiglutide to Zealand". Lugano & Copenhagen....
• [6] Helsinn Healthcare S.A.. (5/19/17). "Press Release: Helsinn to Present at UBS Global Healthcare Conference in New York". Lugano....
• [7] Aadi Bioscience, Inc.. (5/8/17). "Press Release: Aadi Bioscience Closes $23 Million in Series A Funding". Pacific Palisades, CA....
• [8] Helsinn Healthcare S.A.. (5/8/17). "Press Release: Helsinn Investment Fund Invests in Aadi Bioscience". Luxembourg....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.